A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...